VANCOUVER, British Columbia, Aug. 9, 2011 /PRNewswire/ -- Enox Biopharma, Inc., a leader in nitric oxide delivery technology for the prevention of hospital acquired infections today announced on line publication of scientific results demonstrating superior efficacy in blocking growth of E.coli on the surface of nitric oxide releasing devices as compared to current market leader's silver coated catheters. The paper was published by Professor Yossef Av-Gay's lab at the University of British Columbia.
Enox's nitric oxide device technology renders medical devices like catheters and endotracheal tubes antimicrobial by sequestering nitric oxide within them in a stable state. Nitric Oxide, which is released by the device over a period of about 2 weeks once used clinically, is a potent antimicrobial agent without the drug resistance issues that plague antibiotics. Previous peer reviewed publications have demonstrated the antimicrobial properties of catheters treated with our technology in comparison to untreated catheters.
The paper titled "Comparative efficacy of commercially available and emerging antimicrobial urinary catheters against E. coli infection in vitro" was published in the August 2011 issue of the peer reviewed journal UROLOGY. The paper reports results from an investigation of the ability of four different types of catheters to prevent growth of microorganisms suspended in fluid medium (planktonic growth) and on the surface of catheters in the form of a biofilm. The study compared a non-antimicrobial catheter, an Enox nitric oxide releasing catheter, a silver coated catheter and an antibiotic coated catheter. The study concluded that both the Enox and antibiotic catheters were effective in preventing planktonic growth and biofilm formation whereas the silver and uncoated catheters were not.
"This study confirms the superiority of nitric oxide as an antimicrobial," commented Professor Av-Gay, who is the President and Founder of Enox Bio